Roche PD-L1 Bladder Cancer Filing Set For 2016; Investors Hope For Earlier
This article was originally published in The Pink Sheet Daily
Executive Summary
With limited treatment options available for bladder cancer, being first to market with a paradigm-changing PD-1/PD-L1 inhibitor in the indication could be a big commercial opportunity.